CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announced First-Patient-In in the Phase 1 dose escalation and expansion study of CID-103, an investigational novel anti-CD38 monoclonal antibody, in patients with previously treated, relapsed or refractory multiple myeloma.
The study is designed to assess the safety, tolerability, pharmacology and clinical activity of CID-103.
The study is designed to assess the safety, tolerability, pharmacology and clinical activity of CID-103.
Services
CASI Pharmaceuticals, Inc. is a U.S. NASDAQ-listed biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products. CASI has built a portfolio that includes approved and investigational assets. We have offices in Rockville, Maryland, and a wholly-owned subsidiary in Beijing, China, through which our China operations are conducted.
CASI is a U.S. NASDAQ-listed biopharmaceutical company with a platform to develop and accelerate the launch of pharmaceutical products and innovative therapeutics in China, the U.S., and throughout the world. We have offices in Rockville, Maryland, and a wholly owned subsidiary in Beijing, China, through which substantially all of our operations are conducted.
Prior to joining CASI, Dr. He was the CEO of OriGene Technologies, Inc. and remains Chairman of the Board of Directors. He also is the founder and General Partner of Emerging Technology Partners, LLC (ETP), a life sciences focused venture fund established since 2000. Dr. He has been involved in founding or funding over 60 biotech companies throughout his career, some of which went on to be acquired by significantly larger firms.
CNCT19 is a chimeric antigen receptor (CAR) modified T cell (CAR-T). The CD19 antigen is a frequently used target in CAR-T cell therapy for certain hematological malignancies such as certain leukemias and lymphomas. The active therapeutic modality of CNCT19 are T-cells which have been genetically modified to express chimeric antigen receptors (CARs) targeting CD19.
BI-1206 has a novel mode-of-action, blocking the single inhibitory antibody checkpoint receptor FcRIIB to unlock anti-cancer immunity in both liquid and solid tumors. Fc receptors are "antibody checkpoints" that modulate efficacy of tumor-cell direct-targeting antibodies and immune checkpoint-targeting antibodies used in cancer immunotherapy.
Reviews
Be the first to review CASI Pharmaceuticals.
Write a Review
